Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Colorectal Cancer

In brief

The goal of this clinical research study is to learn if minocycline can reduce numbness, pain, and/or loss of motor function in patients with colorectal cancer. In this study, minocycline will be compared to a placebo. The study doctor can explain how the study drug is designed to work. A placebo is not a drug. It looks like the study drug, but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Key facts

Study ID

NCT01906008

Run by

M.D. Anderson Cancer Center

People needed

122

Starts

2013-11-01

Expected to finish

2019-02-14

Last updated by the study team

2020-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a pathologically proven diagnosis of CRC seen either at MD Anderson or LBJ.
• Patients > or = 18 years old.
• Patients who qualify for oxaliplatin-based chemotherapy (in the adjuvant or metastatic setting) and are likely to receive at least 3 months of oxaliplatin.
• Patients who speak English or Spanish (due to language options for the MDASI version being used in this study, we are only recruiting English-speaking or Spanish-speaking patients).
• Patients with an NCI-CTCv4 sensory neuropathy score of 0.
• Patients with adequate renal function (serum creatinine must be < 1.5 times the upper limit of the institutional normal range) and no prior renal disease that in the opinion of the attending physician would make the patient ineligible to receive the study drug . Test results must be no more than 3 months old.
• Patients with adequate hepatic function (total bilirubin must be < 2.0 times the upper limit of the institutional normal range; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be < 3.0 times the upper limit of the institutional normal range). Test results must be no more than 3 months old.
• Patients willing and able to review, understand, and provide written consent.

You may not qualify if…

• Patients continuously taking any minocycline within the last 15 days. Patients who have conditions that potentially preclude use of minocycline as determined by the treating physician.
• Patients continuously taking systemic steroids within the last 15 days.
• Patients with autoimmune disorders (for example, systemic lupus erythematosus or rheumatoid arthritis), who have been treated in the last 3 years.
• Patients who are pregnant; the absence of pregnancy will be confirmed by negative urine test.
• Hypersensitivity to any tetracyclines, or a history of other allergies or drug reactions that in the treating physician's judgment make the patient inappropriate for this study.
• Patients receiving vitamin K antagonist (warfarin).
• Patients with a BMI >40 (Obese Class III criteria).
• Patients who will receive cetuximab or other targeted therapy where physicians may use topical doxycycline to reduce the rash associated with therapy.

Where it is running

• LBJ Hospital — Houston, Texas, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.